Khiron Life Sciences Corp.
Khiron is a leading global medical cannabis company with core operations in Latin America and Europe. Leveraging wholly-owned medical health clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach with physician education programs, scientific expertise, product innovation, and focuses on creating access to drive prescriptions and brand loyalty with patients worldwide. The Company has a sales presence in Colombia, Peru, Germany, UK, and Brazil and is positioned to commence sales in Mexico. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, with an experienced and diverse executive team and Board of Directors.
OTC: KHRNF
IR Website: https://investors.khiron.ca/corporate-information
Headquarters: Toronto, Ontario
Content provided by Khiron Life Sciences on 2-23-22.
TALK TO MANAGEMENT
The Khiron Life Sciences management team is always available to talk to current and potential investors. They're happy to answer any questions you may have and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.
Summary
Khiron is a leading global medical cannabis company with core operations in Latin America and Europe. Leveraging wholly-owned medical health clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach with physician education programs, scientific expertise, product innovation, and focuses on creating access to drive prescriptions and brand loyalty with patients worldwide. The Company has a sales presence in Colombia, Peru, Germany, UK, and Brazil and is positioned to commence sales in Mexico. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, with an experienced and diverse executive team and Board of Directors.
Investor Presentation
Recent News
Khiron Adds Another Clinic Location in Peru
Feb 7, 2022
Khiron Opens New Medical Cannabis Clinic in Colombia
Jan 31, 2022
Mandatory Insurance Coverage for Medical Cannabis Now Expands to More than 50 million Colombians
Jan 4, 2022
Khiron to Participate in the Lytham Partners Winter 2021 Investor Conference
Dec 9, 2021
Khiron Announces Grants of Options and Restricted Share Units
Nov 23, 2022
Management Overview
Alvaro Torres
Chief Executive Officer and Director
Mr. Torres is the founder, CEO and Director of Khiron. He has almost two decades of experience in the Latin American market, including infrastructure projects and project finance, management strategy, team development, and mergers and acquisitions. Mr. Torres was previously head of business development for SNC-Lavalin, Colombia, and was instrumental in growing the company from two people to more than 2,000 people in Colombia over the course of three years. Mr. Torres has overseen the development of projects totaling over $1 billion in capital expenditure, including the development and construction of Colombia’s tallest skyscraper. Mr. Torres holds a Bachelor of Engineering and a Master of Engineering from Rensselaer Polytechnic Institute and an MBA from Georgetown University.
Swapan Kakumanu
Chief Financial Officer
Mr. Kakumanu has more than 25 years of senior finance and operations experience and has served at the senior executive management levels, both in public and private companies, in high growth technology, manufacturing, blockchain, medical device, and oil field services industries. He has held senior roles as President, Chief Executive Officer, Chief Financial Officer, Controller, Company Secretary, and Board Member for public and private companies.
Franziska Katterbach
President, Europe
Franziska Katterbach is an accomplished business executive and legal expert (zugelassene Rechtsanwältin) who brings extensive experience working within Europe's emerging cannabis industry. After completing her legal studies at Universität Leipzig and Landgericht Darmstadt, Franziska joined corporate law firm Dentons, where she was involved high-profile deals in the cannabis sector across multiple jurisdictions. Franziska later served as Director of Legal for Canopy's European operations, prior to joining Khiron.
Risks & Disclosures
This communication is neither an offer to sell nor a solicitation of an offer to buy, nor a recommendation of any securities of the company mentioned herein.
Khiron Life Sciences Corp. (the “Company”) and its counsel have reviewed the content of this page as well as the accompanying presentation (“Company Presentation”) displayed on this page. To the best of its knowledge, the Company does not believe this content to be misleading or inaccurate in any material respect, nor does it believe there are any material omissions with respect to such content. The Company does not believe the contents of the page or the Company Presentation to contain any non-public material information.
Information and opinions presented in the Company Presentation are provided by the Company, and b2i digital makes no representation as to their accuracy or completeness. The information contained on this page is not intended to constitute any form of advice, and the information provided is not intended to provide a sufficient basis on which to make an investment decision. It is not investment research, nor does it constitute a research recommendation, as it does not constitute substantive research or analysis. This information is not to be relied upon in substitution for the exercise of independent judgment.
Information, opinions and estimates contained on this page or in the Company Presentation reflect judgments by the Company as of the original date of publication by the Company and are subject to change without notice. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied is made regarding future performance.
A complete description of the risks and uncertainties relating to the Company and its securities can be found in the company's filings with the U.S. Securities and Exchange Commission available for free at www.sec.gov.
Information on this page may relate to penny stocks, which may also be referred to as low-priced stocks. Penny stocks are low-priced shares typically issued by small companies. Penny stocks involve greater than normal risk, they may be less liquid than other stocks (i.e., more difficult to sell), and there may be less reliable information available regarding such stocks. Investors in penny stocks should be prepared for the possibility that they may lose their entire investment.
B2I DIGITAL, Inc. is a marketing sponsor of the Roth 34th Annual Roth Conference. B2I DIGITAL, Inc. is not an affiliate of Roth Capital Partners, LLC (“Roth”) and is not authorized to represent or act on behalf of Roth ,in any capacity. Roth has not reviewed and approved the content contained on the b2idigital.com website.
